181 related articles for article (PubMed ID: 14735456)
21. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue.
Upadhyay G; Singh R; Agarwal G; Mishra SK; Pal L; Pradhan PK; Das BK; Godbole MM
Breast Cancer Res Treat; 2003 Jan; 77(2):157-65. PubMed ID: 12602914
[TBL] [Abstract][Full Text] [Related]
22. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer.
Riedel C; Dohán O; De la Vieja A; Ginter CS; Carrasco N
Trends Biochem Sci; 2001 Aug; 26(8):490-6. PubMed ID: 11504625
[TBL] [Abstract][Full Text] [Related]
23. The Na+/I- symporter (NIS): mechanism and medical impact.
Portulano C; Paroder-Belenitsky M; Carrasco N
Endocr Rev; 2014 Feb; 35(1):106-49. PubMed ID: 24311738
[TBL] [Abstract][Full Text] [Related]
24. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
25. microRNA-339-5p modulates Na+/I- symporter-mediated radioiodide uptake.
Lakshmanan A; Wojcicka A; Kotlarek M; Zhang X; Jazdzewski K; Jhiang SM
Endocr Relat Cancer; 2015 Feb; 22(1):11-21. PubMed ID: 25404690
[TBL] [Abstract][Full Text] [Related]
26. Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer.
Huang M; Batra RK; Kogai T; Lin YQ; Hershman JM; Lichtenstein A; Sharma S; Zhu LX; Brent GA; Dubinett SM
Cancer Gene Ther; 2001 Aug; 8(8):612-8. PubMed ID: 11571539
[TBL] [Abstract][Full Text] [Related]
27. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
[TBL] [Abstract][Full Text] [Related]
28. Correlation of Na+/I- symporter expression and activity: implications of Na+/I- symporter as an imaging reporter gene.
Vadysirisack DD; Shen DH; Jhiang SM
J Nucl Med; 2006 Jan; 47(1):182-90. PubMed ID: 16391203
[TBL] [Abstract][Full Text] [Related]
29. A perspective view of sodium iodide symporter research and its clinical implications.
Riesco-Eizaguirre G; Santisteban P
Eur J Endocrinol; 2006 Oct; 155(4):495-512. PubMed ID: 16990649
[TBL] [Abstract][Full Text] [Related]
30. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas.
Cho JY; Shen DH; Yang W; Williams B; Buckwalter TL; La Perle KM; Hinkle G; Pozderac R; Kloos R; Nagaraja HN; Barth RF; Jhiang SM
Gene Ther; 2002 Sep; 9(17):1139-45. PubMed ID: 12170377
[TBL] [Abstract][Full Text] [Related]
31. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
Schmutzler C; Köhrle J
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
33. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line.
Jeong H; Kim YR; Kim KN; Choe JG; Chung JK; Kim MK
Nucl Med Biol; 2006 Oct; 33(7):875-82. PubMed ID: 17045167
[TBL] [Abstract][Full Text] [Related]
34. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
35. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy.
Boland A; Ricard M; Opolon P; Bidart JM; Yeh P; Filetti S; Schlumberger M; Perricaudet M
Cancer Res; 2000 Jul; 60(13):3484-92. PubMed ID: 10910060
[TBL] [Abstract][Full Text] [Related]
36. PI3K activation is associated with intracellular sodium/iodide symporter protein expression in breast cancer.
Knostman KA; McCubrey JA; Morrison CD; Zhang Z; Capen CC; Jhiang SM
BMC Cancer; 2007 Jul; 7():137. PubMed ID: 17651485
[TBL] [Abstract][Full Text] [Related]
37. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
Jung KH; Paik JY; Ko BH; Lee KH
J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
[TBL] [Abstract][Full Text] [Related]
38. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression.
Willhauck MJ; Sharif Samani BR; Gildehaus FJ; Wolf I; Senekowitsch-Schmidtke R; Stark HJ; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2007 Nov; 92(11):4451-8. PubMed ID: 17698909
[TBL] [Abstract][Full Text] [Related]
39. Telomerase-driven expression of the sodium iodide symporter (NIS) for in vivo radioiodide treatment of cancer: a new broad-spectrum NIS-mediated antitumor approach.
Riesco-Eizaguirre G; De la Vieja A; Rodríguez I; Miranda S; Martín-Duque P; Vassaux G; Santisteban P
J Clin Endocrinol Metab; 2011 Sep; 96(9):E1435-43. PubMed ID: 21697253
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
Dwyer RM; Bergert ER; O'Connor MK; Gendler SJ; Morris JC
Hum Gene Ther; 2006 Jun; 17(6):661-8. PubMed ID: 16776574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
